Comparative Analysis of SUV Measurements Using Different Correction Methods in Oncological PET/CT Imaging.
NCT ID: NCT07306975
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
80 participants
OBSERVATIONAL
2025-12-10
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET/CT with 18-FDG
* Patients will fast for at least 4 hrs before imaging with blood glucose level (\<200 mg/dl) before intravenous administration of F18-FDG.
* Imaging will be performed approximately 45 to 60 min after 18F-FDG injection, an imaging field of view from the base of skull to mid-thighs with the arms above the head whenever possible is used or otherwise the arms are positioned beside the body.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with increased FDG uptake on tissue associated with non-malignant causes such as diffuse bone marrow FDG uptake or inflammatory.
* Patients with extensive metastasis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aya Kamel Hamed Ahmed
Resident doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hanan Gamal Eldin Mostafa, Professor, doctor
Role: STUDY_CHAIR
Assiut University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
HebatAllah Ahmed AbdelRaoof Askar, Assistant Professor, doctor
Role: CONTACT
Phone: +2001003040898
Email: [email protected]
References
Explore related publications, articles, or registry entries linked to this study.
Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med. 1994 Jan;35(1):164-7.
Nakaichi T, Funamoto K, Yamashita S, Yamamoto H, Yokoyama K. Clinical Usefulness of Standardized Uptake Value Normalized to Lean Body Mass Measured Using a Body Composition Analyzer. Cureus. 2025 May 30;17(5):e85089. doi: 10.7759/cureus.85089. eCollection 2025 May.
Azmi NHM, Suppiah S, Liong CW, Noor NM, Said SM, Hanafi MH, et al. Reliability of standarized uptake value normalized to lean body mass using the liver as a reference organ, in contrast-enhanced 18F-FDG PET/CT imaging. Radiography. 2018;24(2):112-117. doi:10.1016/j.radi.2017.09.006.
Ahmed A, Ali M, Salah H, Eisa RE, Mohieldin H, Omer H, et al. Evaluation of uptake values of FDG: Body surface area Vs. body weight correction. Radiat Phys Chem. 2022;201:110482. doi:10.1016/j.radphyschem.2022.110482 .
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SUV measurements in PET/CT
Identifier Type: -
Identifier Source: org_study_id